InChIKey	IQVRBWUUXZMOPW-PKNBQFBNSA-N
Compound Name	Istradefylline
Canonical SMILES	CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	3
Pfam Stratification	Cross-Family
Avg pChEMBL	7.03
Source	ChEMBL;BindingDB

DrugBank ID	DB11757
Drug Name	Istradefylline
CAS Number	155270-99-8
Groups	approved investigational
ATC Codes	N04CX01
Description	Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.[A184067]...

---

Categories: Adenosine A2 Receptor Antagonists Anti-Parkinson Drugs BCRP/ABCG2 Inhibitors Cytochrome P-450 CYP1A1 Substrates Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2B6 Substrates Cytochrome P-450 CYP2C18 Substrates Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 Substrates Heterocyclic Compounds, Fused-Ring MATE 1 Inhibitors MATE 2 Inhibitors MATE inhibitors Nervous System Neurotransmitter Agents OAT1/SLC22A6 inhibitors OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors P-glycoprotein inhibitors Purinergic Agents Purinergic Antagonists Purinergic P1 Receptor Antagonists

---

Cross-references: BindingDB: 50176050 ChEBI: 134726 CHEMBL431770 ChemSpider: 4470574 PDB: JQ9 PubChem:5311037 PubChem:347828111 RxCUI: 2199015 Wikipedia: Istradefylline ZINC: ZINC000003803921